The effect of Bosentan in the treatment of pulmonary hypertension in patients with COVID-19

Comparison assessment of Bosentan and routine medication on pulmonary hypertension among hospitalized patients with COVID-19

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210710051831N1

Enrollment

Registered

2021-08-09

Start date

2021-08-23

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: COVID-19. Condition 2: COVID-19. COVID-19, virus not identified COVID-19, virus identified

Interventions

Intervention 1: Intervention group: The case group in addition to the drugs used in the treatment of COVID-19 (approved by the National Committee), is treated with Bosentan 62.5mg twice a day for 10 d

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with COVID-19 referred to Boali Sina hospital, Qazvin during 1400 patients with COVID-19 pneumonia and pulmonary hypertension Willingness to participate in a research project Signing the informed consent form

Exclusion criteria

Exclusion criteria: Age range under 14 years Pregnant women History of pulmonary hypertension Severe obstructive pulmonary disease

Design outcomes

Primary

Measure	Time frame
Pulmonary artery systolic pressure. Timepoint: Before and 10 days after the intervention. Method of measurement: Echocardiography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFahimeh Shokrollahi

Qazvin University of Medical Sciences

fahimeshorollahi@yahoo.com+98 28 3333 2930

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026